research use only

CA77.1 Autophagy activator

Cat.No.S6395

CA77.1 (CA) is a potent, brain-penetrant and orally active activator of chaperone-mediated autophagy (CMA) for the treament of Alzheimer's disease (AD).
CA77.1 Autophagy activator Chemical Structure

Chemical Structure

Molecular Weight: 297.74

Jump to

Quality Control

Batch: Purity: 99.93%
99.93

Solubility

In vitro
Batch:

DMSO : 30 mg/mL (100.75 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 297.74 Formula

C16H12ClN3O

Storage (From the date of receipt) 3 years -20°C powder
CAS No. 2412270-22-3 -- Storage of Stock Solutions

Synonyms CA Smiles CC(=O)NC1=CC=C(C=C1)C2=NC3=CC=C(Cl)C=C3N=C2

Mechanism of Action

Targets/IC50/Ki
CMA
In vivo

CA77.1 activates CMA in vitro in dose- and time-dependent manner without affecting macroautophagy and when administering in vivo demonstrate brain penetrance with favorable pharmacokinetics, activation of CMA in brain of KFERQ-Dendra mice, and absence of blood or major organs toxicity after 3 months of daily treatment.

References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01199250 Not yet recruiting
Lynch Syndrome|Recurrent Uterine Corpus Carcinoma|Stage I Uterine Corpus Cancer|Stage II Uterine Corpus Cancer|Stage III Uterine Corpus Cancer|Stage IV Uterine Corpus Cancer
Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation
January 2100 --
NCT01164735 Not yet recruiting
Recurrent Uterine Corpus Carcinoma|Stage III Uterine Corpus Cancer|Stage IV Uterine Corpus Cancer
Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation
January 2100 --
NCT06356558 Not yet recruiting
Surgery|Health Knowledge Attitudes Practice|Colorectal Disorders
University of Alabama at Birmingham|National Cancer Institute (NCI)
May 2026 Not Applicable
NCT06353282 Not yet recruiting
PTSD Post Traumatic Stress Disorder|Adolescents|Psychotherapy
University of California Los Angeles
July 1 2025 Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map